Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Research & Development (2023 - 2024)

Kura Oncology (KURA) has disclosed Research & Development for 2 consecutive years, with $52.3 million as the latest value for Q4 2024.

  • Quarterly Research & Development rose 60.66% to $52.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $170.0 million through Dec 2024, up 47.5% year-over-year, with the annual reading at $251.1 million for FY2025, 47.72% up from the prior year.
  • Research & Development for Q4 2024 was $52.3 million at Kura Oncology, up from $41.7 million in the prior quarter.
  • The five-year high for Research & Development was $52.3 million in Q4 2024, with the low at $25.2 million in Q1 2023.